Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Current Opinion in Rheumatology
|
July 20, 2012
Lipids and eicosanoids in fibrosis: emerging targets for therapy
Flavia V Castelino
Arthritis Research & Therapy
|
August 26, 2010
Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management
Flavia V Castelino, John Varga
Clinical and Experimental Rheumatology
|
August 30, 2024
Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases
Flavia V Castelino, Ayodeji Adegunsoye
Expert Review of Clinical Immunology
|
October 31, 2013
Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development
Flavia V Castelino, John Varga
ACR Open Rheumatology
|
March 29, 2021
Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases
Flavia V Castelino, Teng Moua
Current Opinion in Rheumatology
|
September 6, 2014
Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy
Flavia V Castelino, John Varga
Therapeutic Advances in Respiratory Disease
|
June 17, 2017
Evaluation and management approaches for scleroderma lung disease
Sara R Schoenfeld, Flavia V Castelino
Current Opinion in Rheumatology
|
September 21, 2018
Recent progress in systemic sclerosis-interstitial lung disease
Flavia V Castelino, Paul F Dellaripa
Rheumatic Diseases Clinics of North America
|
April 4, 2015
Interstitial lung disease in scleroderma
Sara R Schoenfeld, Flavia V Castelino
Current Rheumatology Reports
|
July 17, 2009
Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib
Flavia V Castelino, Swati Bhattacharyya, John Varga
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Current Opinion in Rheumatology
|
July 20, 2012
Lipids and eicosanoids in fibrosis: emerging targets for therapy
Flavia V Castelino
Arthritis Research & Therapy
|
August 26, 2010
Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management
Flavia V Castelino, John Varga
Clinical and Experimental Rheumatology
|
August 30, 2024
Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases
Flavia V Castelino, Ayodeji Adegunsoye
Expert Review of Clinical Immunology
|
October 31, 2013
Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development
Flavia V Castelino, John Varga
ACR Open Rheumatology
|
March 29, 2021
Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases
Flavia V Castelino, Teng Moua
Current Opinion in Rheumatology
|
September 6, 2014
Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy
Flavia V Castelino, John Varga
Therapeutic Advances in Respiratory Disease
|
June 17, 2017
Evaluation and management approaches for scleroderma lung disease
Sara R Schoenfeld, Flavia V Castelino
Current Opinion in Rheumatology
|
September 21, 2018
Recent progress in systemic sclerosis-interstitial lung disease
Flavia V Castelino, Paul F Dellaripa
Rheumatic Diseases Clinics of North America
|
April 4, 2015
Interstitial lung disease in scleroderma
Sara R Schoenfeld, Flavia V Castelino
Current Rheumatology Reports
|
July 17, 2009
Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib
Flavia V Castelino, Swati Bhattacharyya, John Varga
Page
of 5